For instance, many cancers show an increased activation of insulin-like growth factor-1 (IGF-1) signaling pathways and PRDM2a/RIZ1 is able to counteract the IGF-1 receptor and the downstream signaling cascade components ERK1/2 and AKT (Figure 3B) [73]. This evidence concerns the gene PRDM2 and cancer.